EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis

Zhen Yuan, Hao Cui, Shuyuan Wang, Wenquan Liang, Bo Cao, Liqiang Song, Guibin Liu, Jun Huang, Lin Chen, Bo Wei

Frontiers in Oncology · 26.01.2023 · 13

DOI: 10.3389/fonc.2023.1103320 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 26.01.2023. Verfasst von Zhen Yuan und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Nankai University, Tianjin, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have shown promising prospects in locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) immunotherapy, but their efficacy in neoadjuvant settings remains unclear. This study aimed to assess the efficacy and safety of integrating programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors into neoadjuvant chemotherapy (NACT) of GC/GEJC treatment.

Methods

PubMed, Cochrane Library, Embase, ClinicalTrials.gov, and main oncology conference databases were systematically searched up to 19 November 2022, and randomized controlled trials (RCTs) and cohort studies that evaluated the efficacy and safety of PD-1/PD-L1 inhibitors plus NACT were included. The main outcomes were pathological complete response (pCR), major pathological response (MPR), R0 resection rate, and treatment-related adverse events (TRAEs).

Results

A total of 753 patients from 20 prospective studies were included in this meta-analysis. The pooled pCR and MPR rates from studies reporting were 21.7% [95% confidence interval (CI), 18.1%–25.5%] and 44.0% (95% CI, 34.1%–53.8%), respectively. The pooled incidence rate of total TRAEs was 89.1% (95% CI, 82.7%–94.3%), and the incidence rate of grade 3 to 4 TRAEs was 34.4% (95% CI, 17.8%–66.5%). The pooled R0 resection rate was reported to be 98.9% (95% CI, 97.0%–99.9%). Subgroup analysis has not found significant differences in efficacy and safety among different PD-1/PD-L1 inhibitors. Moreover, the efficacy in patients with positive PD-L1 expression (combined positive score ≥1) was comparable with that in the entire study population [pCR, 22.5% vs. 21.2% (p > 0.05); MPR, 48.6% vs. 43.7% (p > 0.05)].

Conclusion

This systematic review and meta-analysis found that PD-1/PD-L1 inhibitors combined with NACT for locally advanced GC/GEJC were well tolerated and may confer therapeutic advantages. The integration of ICIs into NACT has shown the potential for application in any PD-L1 expression population.

Schlagwörter

Stichwörter der Autor:innen

PD-1/PD-L1 inhibitorsgastric adenocarcinomagastroesophageal junction adenocarcinomaimmune checkpoint inhibitorsneoadjuvant immunotherapy

Autor:innen und Institutionen

  • School of Medicine, Nankai University, Tianjin, China.
  • Department of General Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Department of Radiotherapy, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Yuan, Z., Cui, H., Wang, S., Liang, W., Cao, B., Song, L., Liu, G., Huang, J., Chen, L., & Wei, B. (2023). Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1103320

Vancouver

Yuan Z, Cui H, Wang S, Liang W, Cao B, Song L, et al. Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1103320

BibTeX
@article{Yuan2023,
  author = {Yuan, Zhen and Cui, Hao and Wang, Shuyuan and Liang, Wenquan and Cao, Bo and Song, Liqiang and Liu, Guibin and Huang, Jun and Chen, Lin and Wei, Bo},
  title = {Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fonc.2023.1103320}
}
Kostenlos starten →